Pulmonology

Dexamethasone should also be used for up to 10 days in patients with COVID-19 who require supplemental oxygen but are not mechanically ventilated.

Where do investigators go next with the 8000-plus COPD patient research?

Both dosage groups of the study drug achieved at least a 50-meter increase from baseline to week 24 on the six-minute walk distance test.

Treatment with treprostinil of up to 12 breaths per session four-times per data was well-tolerated, with a safety profile consistent with previous studies.

In an era of triple therapy combinations, what might a tailored approach look like?

New findings from the 8000-plus patient ETHOS trial shows triple inhaler therapy siginificantly betters patient mortality and symptoms over 52 weeks versus dual therapy.

The FDA is allowing the pen to be used for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) patients at least 12 years old.

The therapy reduces death by 35% in patients with respiratory complications.

What risks of severity do patients face with viral infection?

A look at how the rare pulmonary disease field of research has been limited.

A look at the appropriate referral and promising agents for care of the rare pulmonary disease.

Greg Cosgrove, MD, explains how the respiratory condition can be overlooked by patients and clinicians.

A new Canadian Thoracic Society guidance sets recommendations for continued or halted use of inhaled steroids, nebulizers, biologics, and more.

The biologic has now shown significant efficacy in treating 4 different atopic or type 2 inflammatory diseases.

How clinical data for the interleukin-targeting class will begin to dictate more treatement decisions and research progression.

Asthmatic infants often suffer from other comorbidities throughout their lives.

Blood eosinophil count, exacerbation rate, and time to exacerbation were all bettered among patients who sustained therapy versus those who discontinued.

In an abstract presenting during the ATS conference, investigators find infants with asthma are surprisingly older on the epigentic clock.

New findings from ATS show the residual effects of vaping-associated lung distress.

The lead PATHWAY investigator explains the intent and outcomes from the most recent phase 2B findings.

A discussion with a study author on promising new findings for the combination inhaler therapy.

There are a number of reasons why identifying obstructive sleep apnea in infants is difficult, but new research shows feeding dysfunction could be an early link.

Little is understood about the systemic markers of worsening COPD. Investigators have observed at least 3 novel pathways.

A new assessment shows risk reduction is even more significant among COPD patients who have smoked.

A six-month study shows the common OSA therapy could have long-term benefit for reducing eventual cardiovascular risk.